These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29163482)

  • 1. Current Advances in γδ T Cell-Based Tumor Immunotherapy.
    Lo Presti E; Pizzolato G; Gulotta E; Cocorullo G; Gulotta G; Dieli F; Meraviglia S
    Front Immunol; 2017; 8():1401. PubMed ID: 29163482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives of gammadelta T cells in tumor immunology.
    Kabelitz D; Wesch D; He W
    Cancer Res; 2007 Jan; 67(1):5-8. PubMed ID: 17210676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of gamma delta T cells with multivalent immunity.
    Deniger DC; Moyes JS; Cooper LJ
    Front Immunol; 2014; 5():636. PubMed ID: 25566249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
    Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ
    Front Immunol; 2022; 13():915837. PubMed ID: 35784326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of human gammadelta T lymphocytes for immunotherapy of cancer.
    Kabelitz D; Wesch D; Pitters E; Zöller M
    Int J Cancer; 2004 Dec; 112(5):727-32. PubMed ID: 15386388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. γδ T Cell-Mediated Immune Responses in Disease and Therapy.
    Latha TS; Reddy MC; Durbaka PV; Rachamallu A; Pallu R; Lomada D
    Front Immunol; 2014; 5():571. PubMed ID: 25426120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
    Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
    J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire.
    Dimova T; Brouwer M; Gosselin F; Tassignon J; Leo O; Donner C; Marchant A; Vermijlen D
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):E556-65. PubMed ID: 25617367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. γδ cell-based immunotherapy for cancer.
    Lo Presti E; Corsale AM; Dieli F; Meraviglia S
    Expert Opin Biol Ther; 2019 Sep; 19(9):887-895. PubMed ID: 31220420
    [No Abstract]   [Full Text] [Related]  

  • 15. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
    Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
    Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy with γδ T cells: many paths ahead of us.
    Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
    Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
    Gogoi D; Chiplunkar SV
    Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells.
    Halary F; Pitard V; Dlubek D; Krzysiek R; de la Salle H; Merville P; Dromer C; Emilie D; Moreau JF; Déchanet-Merville J
    J Exp Med; 2005 May; 201(10):1567-78. PubMed ID: 15897274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
    Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
    J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.